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Plasmodium falciparum parasites express and traffick numerous proteins into the red blood cell (RBC), where some associate specifically with
the membrane skeleton. Importantly, these interactions underlie the major alterations to the modified structural and functional properties of the
parasite-infected RBC. P. falciparum Erythrocyte Membrane Protein 3 (PfEMP3) is one such parasite protein that is found in association with the
membrane skeleton. Using recombinant PfEMP3 proteins in vitro, we have identified the region of PfEMP3 that binds to the RBC membrane
skeleton, specifically to spectrin and actin. Kinetic studies revealed that residues 38–97 of PfEMP3 bound to purified spectrin with moderately
high affinity (KD(kin) =8.5×10
−8 M). Subsequent deletion mapping analysis further defined the binding domain to a 14-residue sequence
(IFEIRLKRSLAQVL; KD(kin) =3.8×10
−7 M). Interestingly, this same domain also bound to F-actin in a specific and saturable manner. These
interactions are of physiological relevance as evidenced by the binding of this region to the membrane skeleton of inside-out RBCs and when
introduced into resealed RBCs. Identification of a 14-residue region of PfEMP3 that binds to both spectrin and actin provides insight into the
potential function of PfEMP3 in P. falciparum-infected RBCs.
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Infection with the Apicomplexan parasite Plasmodium
falciparum causes the most severe form of human malaria,
resulting in millions of deaths worldwide each year [1]. When
compared to normal human red blood cells (RBCs), infected
RBCs (IRBCs) have dramatically altered structural and
functional properties that include decreased deformability and
the appearance of electron dense protrusions, or knobs, at the
RBC membrane that mediate binding to the vascular endothe-
lium (see Cooke et al. for review [2]). These parasite-induced
modifications to the RBC are secondary to the synthesis and
trafficking of a number of parasite-encoded proteins into the
RBC.While some trafficked proteins remain soluble in the RBC
cytosol, others are found in complexes with components of the
RBC membrane skeleton or with other parasite-encoded pro-
teins (see Cooke et al., for recent reviews [2,3]).
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RBC skeleton is spectrin. Spectrin is a flexible rod-like protein
that is composed of two non-identical subunits, α and β [4], that
associate in an anti-parallel manner to form αβ heterodimers.
Heterodimers associate in a head to head fashion to form (αβ)2
tetramers, and these tetramers are in turn linked into a network
by interactions with actin filaments, protein 4.1 and ankyrin (see
Bennett and Gilligan for review [5]). The membrane skeleton is
connected to the overlying cell membrane via interactions with
protein 4.1 and glycophorins C and D (GPC and GPD, respec-
tively), and between ankyrin and band 3 (see Lux and Palek
for review [6]). Many P. falciparum proteins are trafficked to
the RBC membrane, including the antigenically variable adher-
ence ligand P. falciparum Erythrocyte Membrane Protein 1Fig. 1. Mapping the region of PfEMP3 that binds to the RBC skeleton. (A) Schematic
peptide repeat region. Repeat regions are shown in solid, shaded boxes, whereas non-r
schematic. The intron splice site, located between the first and second exon of pfemp
representation of PfEMP3 and the initial sub-fragments used to analyse binding to th
schematic and adjacent to the fragment name (shown in brackets), respectively. (C) Pu
was resolved by SDS-PAGE in 10% polyacrylamide gels, prior to visualisation with C
(lane 3), -FIII (lane 4), -FIV (lane 5), -FV (lane 6), -FIa (lane 7) and -FIb (lane 8). (D)
BSA (lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18) were coated on the wells of the 96 well pl
(lanes 1, 2, 13 and 14), MBP-PfEMP3-FI (lanes 3 and 4), -FII (lanes 5 and 6), -FIII (la
and -Flb (lanes 17 and 18). -FI, and its sub-fragment -FIa bound to IOVs (lanes 3 a
(lane 11). MBP did not bind to either IOVs (lanes 1 and 13) or BSA (lanes 2 and 1(PfEMP1), Knob Associated Histidine Rich Protein (KAHRP),
Mature parasite-infected Erythrocyte Surface Antigen (MESA)
and Ring-infected Erythrocyte Surface Antigen (RESA; (see
Cooke et al., for review [2]). Previously, we and others have
performed detailed studies to identify the interactions of these
proteins with components of the RBC skeleton and define the
specific sub-domains involved. A 48-residue region of RESA
that has been shown to bind to spectrin [7] resulted in increased
resistance against heat shock of the IRBC [8,9]. A 19-residue
region ofMESA binds to the 30-kDa region of protein 4.1 [10] in
an interaction that displaces p55 from its normal host cell
binding partner 4.1R, thereby potentially modulating the ternary
4.1R–GPC–p55 complex and altering the stability of the mem-
brane skeleton in IRBCs [11]. KAHRP, which is necessary forrepresentation of PfEMP3 and representative sequences located in each distinct
epeat regions are shown in open boxes. Residue numbers are indicated above the
3 is indicated by the division at residues 37–38 on the schematic. (B) Schematic
e RBC skeleton. Residue numbers and fragment lengths are indicated above the
rified MBP-PfEMP3 fusion proteins. 2 μg (total protein) of each purified protein
oomassie Brilliant Blue. The protein samples are: MBP (lane 1), -FI (lane 2), -FII
IOV binding assay immunoblots. IOVs (lanes 1, 3, 5, 7, 9, 11, 13, 15 and 17) and
ate prior to adding MBP–PfEMP3 fusion proteins or MBP control protein: MBP
nes 7 and 8), FIV (lanes 9 and 10), -FV (lanes 11 and 12), -FIa (lanes 15 and 16)
nd 15) but not to BSA (lanes 4 and 16). Residual levels of -FV bound to IOVs
4).
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ankyrin in the membrane skeleton [14,15] via a 72-residue
region in the middle of KAHRP that binds to the repeat 4 region
of α-spectrin (αR4) [16]. KAHRP also binds to the band 3-
binding domain of ankyrin via the 5′ repeat region of the protein
[15]. The cytoplasmic tail of PfEMP1 (VARC region) binds to
both KAHRP [17] and to RBC spectrin and actin [14,18]. The
histidine-rich, 5′ and 3′ repeats regions of KAHRP bind to
several different regions within the cytoplasmic tail of PfEMP1
[19]. Together these KAHRP–PfEMP1–spectrin–actin interac-
tions have been proposed to cluster PfEMP1 at the knobs and
anchor PfEMP1 in the IRBC membrane; an interaction that is
essential for adhesion of IRBCs to endothelial cells under flow
conditions [12].
P. falciparumErythrocyteMembrane Protein 3 (PfEMP3) is an
approximately 315 kDa protein that is synthesised by mature-
stage parasites and exported to the RBC membrane [20–23]. The
pfemp3 gene is located in the subtelomeric region of chromosome
two, adjacent to kahrp [24–26]. pfemp3 comprises two exons; a
structure typical for many parasite proteins that are trafficked to
the RBC skeleton. It contains the VTS/PEXEL motif (RSLAQ;
that signals export to the RBC; [27,28]) and repetitive and non-
repetitive highly charged sequences (Fig. 1A; [21]). Parasites
generated by gene-specific targeted disruption of pfemp3 haveTable 1
Oligonucleotide primer sequences
Primer Fragment a
p766 FI (+), FIa (+), FIa.1 (+)
p767 FI (−), FIb (−)
p768 FII (+)
p769 FII (−)
p773 FIII (−)
p774 FIV (+)
p775 FIV (−)
p776 FIII (+)
p797 FV (−)
p799 FV (+)
p942 FIa (−), FIa.4 (−), FIaΔFIa.1 (−)
p943 FIb (+)
p994 FIa.1 (−)
p995 FIa.2 (+), FIaΔFIa.1 (+)
p996 FIa.2 (−)
p997 FIa.3 (+)
p998 FIa.3 (−)
p999 FIa.4 (+)
p1107 FIaΔ53 (+)
p1108 FIaΔ67 (+)
p1109 FIaΔ83 (+)
p1110 FIaΔ53 (−), FIaΔ67 (−), FIaΔ83 (−)
p1236 54–83 (+), 54–98 (+)
p1237 54–83 (−)
p1238 54–98 (−)
p1212 54–67 (+)
p1211 54–67 (−)
p1245 38–53 (+)
p1246 38–53 (−)
Oligonucleotide primers sequences used in the construction of the pfemp3 DNA fra
a (+) and (−) refer to coding (forward) and non-coding (reverse) DNA sequences
b Gene specific sequence shown in upper case; non-complimentary sequence shodemonstrated that PfEMP3 expression is not essential for the
formation of knobs or for adhesion under flow conditions [29].
RBCs infected with genetically mutated parasites expressing
truncated PfEMP3, however, do show decreased adherence,
possibly resulting from the accumulation of PfEMP3 at the RBC
membrane and reduced expression of PfEMP1 on the RBC
membrane surface. In contrast, PfEMP3 null parasites show only
a modest decrease in adhesion [29]. Taken together, these data
suggest a role for PfEMP3 in transport and expression of PfEMP1
at the membrane surface [29]. To date, the specific interactions
that localise PfEMP3 at the IRBC skeleton have not been
characterised.
Here, we have examined the association of PfEMP3 with the
RBCmembrane skeleton. Using a series of recombinant PfEMP3
fragments in vitro with inside-out vesicles (IOVs), formed from
normal human RBCs and purified spectrin and actin, we have
defined the binding region of PfEMP3 to a 14-residue sequence.
Biosensor interaction assays yielded kinetic data indicative of a
moderate affinity interaction between PfEMP3 fusion proteins
and spectrin (KD(kin) of at least 3.8×10
−7 M), and F-actin co-
sedimentation interaction assays demonstrated that PfEMP3
binds F-actin in a specific and saturable manner. Continued
elucidation of PfEMP3 and other interactions will facilitate con-
struction of a detailed model of the protein interactions occurringSequence (5′→3′) b
ccgagatctTTTACGGTTGTTAAGAAT
cgagaattcttaTGGTTCATGTTCTAAT
cgcggatccCCAACCAAATTACCTGAA
cgagaattcttaTCTAGATTTTCGCGTGC
cgcgaattcttaCATGTTTCCTATACTT
cgaggatccATAGGAAACATGGAACAA
ccggaattcttaTCCTTCACTAGGTGTAT
cgaggattcTCTGATGGATTAAAAGAA
cgcgaattcttaATTTTTTTTTCCTCTCAA
cgaggatccGATTTAAAGAATAAAGCTA
ccggaattcttaTAGTTCATTTATAGCAC
caatggatccAATGAACTAAAAGAAAGG
ccggaattcttaCTCTTTTCTTTTATGATCCCTG
cgcggattcGCTTTAAAACAGAAAACT
ccggaattcttaCTTTAATGCTTCTCCATTTA
cgcggatccGAAAAAGAAAATAAAGAAACA
ccggaattcttaTTTCAAATCCTTTTCTAC
cgcggatccGAAATGGAATTGAAAGAGAAG
ggggacaagtttgtacaaaaaagcaggcttaATATTTGAAATAAGACTTAAAAG
ggggacaagtttgtacaaaaaagcaggcttaGGGAATACAAGGTTAAGC
ggggacaagtttgtacaaaaaagcaggcttaGAGGCATTAAAAGAAAAGC
ggggaccactttgtacaagaaagctgggtcTAGTTCATTTATAGCAC
ccggaattcATATTTGAAATAAGACTTAAAAG
cccaagcttttaCTTAGTTCTAGGATCCCTTAC
cccaagcttttaCTCTTTTCTTTTATGATCCCTG
aattcATATTTGAAATAAGACTTAAAAGATCATTAGCCCAGGTTTTGtaag
gatccttaCAAAACCTGGGCTAATGATCTTTTAAGTCTTATTTCAAATATg
ccggaattcTTTACGGTTGTTAAGAAT
cccaagcttttaATTATACACATTGACA
gments.
, respectively.
wn in lower case and enzyme restriction sites are underlined.
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standing of the complex structural modifications of IRBCs that
ultimately result in severe P. falciparum malaria.
2. Materials and methods
2.1. Construction of pMAL-c2 clones, and expression and purification
of recombinant proteins
Specific oligonucleotide primers (Table 1) designed using the pfemp3
nucleotide sequence [25], were used to PCR amplify regions of pfemp3 from
P. falciparum 3D7 genomic DNA. PCR products were cloned into the pMAL-c2
Maltose-Binding Protein (MBP) expression plasmid (New England Biolabs,
Beverly MA, USA) and the nucleotide sequence and codon reading frame
confirmed by automated sequencing. MBP-PfEMP3 fusion proteins were
expressed and purified from appropriate Escherichia coli BL21(DE3) (Novagen
Inc., Milwaukee, WI, USA) strains using standard techniques [30]. Purified
proteins were dialysed overnight against phosphate-buffered saline (PBS;Fig. 2. Finer mapping of the region of PfEMP3 that binds to the skeleton. (A) Sch
PfEMP3 sub-fragments and deletion mutant proteins. (B) Purified MBP-PfEMP3 fus
PAGE, prior to visualisation with Coomassie Brilliant Blue. The protein samples are: -
-FIaΔ53 (lane 6), -FIaΔ67 (lane 7) and -FIaΔ83 (lane 8). (C and D) IOV binding assa
(lanes 2, 4, 6, 8, 10, 12, 14, 16,18, 20, 22 and 24) were coated on the wells of the 96 w
MBP (lanes 1, 2, 11, 12, 17 and 18), -FIa.1 (lanes 3 and 4), -FIa.2 (lanes 5 and
-FIaΔFIa.1 (lanes 15 and 16), -FIaΔ53 (lanes 19 and 20), -FIaΔ67 (lanes 21 and 22)
(lane 3) and not to BSA (lane 4), thereby mapping the membrane skeleton binding r
binding fragment FIa, resulting in the generation -FIaΔFIa.1, abolished binding to I
region, using -FIaΔ53, -FIaΔ67 and -FIaΔ83, showed binding of -FIaΔ53 to IOVs
IOVs (lanes 21 and 23, respectively) or BSA (lanes 22 and 24, respectively).10 mMNa2HPO4/NaH2PO4, pH 7.4, containing 0.15 M NaCl) at 4 °C, with one
buffer change before proteins were concentrated by centrifugal filtration. Total
protein concentrations were determined by Bio-Rad Protein Assays (Bio-Lab
Laboratories, Hercules, CA, USA).
2.2. In vitro binding assays using IOVs
Inside out vesicles (IOVs) were prepared from normal human RBCs [10] and
resuspended in IOV Incubation Buffer (IB; 138 mM NaCl, 5 mM KCl, 6 mM
Na2HPO4, 5 mM glucose, pH 9.0). IOV binding assays were performed using
previously described methods [17]. Briefly, IOVs diluted in IB were used to coat
wells of 96 well microtiter plates (Dynatech Laboratories, Inc., Chantilly VA,
USA) overnight at 4 °C.Wells were then blocked overnight at 4 °Cwith 5% (w/v)
BSA in IB, before washing twice with IB. Then, 0.5–4 μg of total recombinant
MBP-PfEMP3 fusion proteins diluted in IB containing 0.05% (v/v) Tween 20
were added to each well and incubated overnight at 4 °C. Wells were then
washed 5 times with IB before proteins were stripped from the wells using
heated (70 °C) reducing sample buffer. Proteins were resolved by SDS-PAGE
and transferred to Polyscreen® polyvinylidene difluoride (PVDF) membraneematic representation of PfEMP3-FI region (residues 38–592) and the smaller
ion proteins. 2 μg (total protein) of each purified protein was resolved by SDS-
FIa.1 (lane 1), -FIa.2 (lane 3), -FIa.3 (lane 3), -FIa.4 (lane 4), -FIaΔFIa.1 (lane 5),
y immunoblots. IOVs (lanes 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23) and BSA
ell plate prior to adding MBP-PfEMP3 fusion proteins or MBP control protein:
6), -FIa.3 (lanes 7 and 8), -FIa.4 (lanes 9 and 10), -FIa (lanes 13 and 14),
and -FIaΔ83 (lanes 23 and 24). The sub-fragment of -Fla, FIa.1 bound to IOVs
egion of PfEMP3 to a 60-residue region. Deletion of these 60 residues from the
OVs (lane 15). Finer deletion analysis was performed to dissect the 60-residue
(lane 19) but not to BSA (lane 20). Both -FIaΔ67 and -FIaΔ83 did not bind to
Fig. 3. Membrane skeleton association of PfEMP3 FI. TX100 detergent
extractions were performed on lysed and resealed RBCs that had been incubated
with 5 μM purified MBP-PfEMP3-FI or -FV. TX100 soluble and insoluble
fractions were resolved by SDS-PAGE and immuno-blotted with anti-MBP
antiserum. MBP-PfEMP3-FI was detected in both the TX100 soluble and
insoluble fractions (lanes 1 and 2, respectively). -FV, a region of PfEMP3 that
does not bind to the membrane skeleton, was detected only in the TX100 soluble
fraction (lane 3) but not the TX100 insoluble fraction (lane 4). The control
TX100 soluble and insoluble fractions of normal lysed and resealed (no MBP
fusion protein) RBCs are shown in lanes 5 and 6, respectively.
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detected via immunoblotting using a primary polyclonal rabbit anti-MBP anti-
serum (J. Bettadapura, Monash University) and secondary anti-rabbit Ig-
horseradish peroxidase conjugate (Silenus Labs Pty. Ltd., Melbourne VIC,
Australia). Autoradiographic images were obtained using NEN Renaissance™
Western Blot chemiluminescence reagent (NEN Life Science Products Inc.,
Boston MA, USA).
2.3. Triton X-100 detergent solubility
Triton X-100 (TX100) detergent solubilities were performed on lysed and
resealed RBCs pre-incubated with MBP-PfEMP3 fusion proteins. Lysis and
resealing was performed as previously described [31]. Briefly, 1 ml of 75%
haematocrit RBCs was dialysed against cold hypotonic buffer (5 mM KPO4 pH
7.4, 20 mM KCl) for 80 min at 4 °C, in the presence or absence of desired MBP
fusion proteins. RBCs were then resealed by dialysing against pre-warmed
isotonic buffer (5 mM KPO4 pH 7.4, 160 mMKCl, 5 mM glucose) for 60 min at
37 °C, washed extensively with PBS before extraction with PBS containing
1.0% (v/v) TX100 on ice for 20 min in the presence of protease inhibitors
(Roche Diagnostics, Castle Hill NSW, Australia). Samples were centrifuged at
13,000 rpm for 5 min at 4 °C before removal of the supernatant. The TX100
insoluble pellet was then washed in PBS/TX100/protease inhibitor solution
before resuspension in PBS containing 2% (w/v) SDS and incubated at room
temperature for 20 min in the presence of protease inhibitors. Samples were then
centrifuged as before and the pellet and supernatant fractions collected. Samples
were resolved in 12% (w/v) polyacrylamide gels, before western blot detection
was performed (as above) using polyclonal rabbit-anti-MBP antiserum.
2.4. In vitro binding assays using spectrin
Spectrin binding assays were performed in a similar manner to the IOV
binding assays, with some modifications. Briefly, PBS was used instead of IB
and 100 ng of purified human spectrin (Sigma, Castle Hill NSW, Australia) was
used to coat the wells of a 96-well microtitre plate (Dynatech Laboratories Inc.,
Chantilly VA, USA). Assays were then processed as described above.
2.5. Binding assays using resonant mirror detection
Protein interactions were studied using the resonant mirror detection method
[32–34] of the IAsys™ (Affinity Sensors, Cambridge, UK), using previously
described methods [17]. Spectrin or BSA were immobilised on aminosilane
cuvettes, and the PfEMP3 fusion proteins added in aqueous solution.
2.6. Actin co-sedimentation assays
Monomeric G-actin (Cytoskeleton, Denver CO, USA; ≥95% pure (by SDS-
PAGE analysis) was polymerised to 0.4 mg/ml in the presence of 50 mM KCl,
2 mM MgCl2, 1 mM ATP for 1 h at room temperature. F-actin (5 μM) and
recombinant MBP-PfEMP3 fusion proteins (5 μM) were incubated in PBS for
30min at room temperature and then centrifuged at 25 °C for 10min at 85,000 rpm
(313,000×g) in a Beckman Optima™ TLX ultracentrifuge using a TLA 120.2
rotor. The pellet was reconstituted into twice the original sample volume and equal
volumes of pellet and supernatant were resolved by SDS-PAGE in 10% (w/v)
polyacrylamide gels. Gels were stained with Coomassie Brilliant Blue or
transferred to PVDF for immunoblot detection using polyclonal anti-MBP
antiserum. Immunoblots were performed as detailed above, and the resulting
autoradiographic data analysed by densitometry using the public domain NIH
Image program (http://rsb.info.nih.gov/nih-image/). The percentage protein in the
pellet was then calculated in both the presence and absence of F-actin, before
subtraction of the% protein in the pellet in the absence of F-actin. The graphed data
were obtained from two independent assays (mean±standard deviation).
Actin co-sedimentation assays were also used to demonstrate specificity and
saturability of the interaction between PfEMP3 and F-actin. Briefly, PfEMP3-FIa
was titrated from 5 μM to 0.0 μM, alongside the negative interaction control protein
-FV (2.5 μM and 1.25 μM). Pellet and supernatant fractions were processed for
immunoblot detection as described above. A saturation of binding curve was
constructed from the data obtained from a representative co-sedimentationexperiment by densitometric analysis and subsequent subtraction of the signal
obtained for the presence of non-binding -FV in the pellet. Equal loading of pellet
and supernatant samples was demonstrated by probing duplicate blots with
monoclonal anti-actin antibodies (Sigma, Castle Hill NSW, Australia).3. Results
3.1. Cloning, protein expression and purification
The P. falciparum pfemp3 gene possesses a typical two exon
gene structure and VTS/PEXELmotif (RSLAQ) that are common
to many genes that encode proteins that are trafficked from the
intracellular parasite into the RBC. pfemp3 possesses a first exon
of 108 bp separated from a downstream second 7.2 kb exon by an
intronic sequence (Fig. 1A). Lack of PCR amplification of the full-
length 7.2 kb second exon P. falciparum 3D7 genomic DNA
precluded the expression and use of full length PfEMP3 proteins
during the course of this investigation. Therefore, a fragment-
based approach was used, in which defined fragments that are
representative of the highly repetitive protein sequences encoded
by the second exon of pfemp3 were PCR amplified, cloned into
the pMAL-c2 expression vector, sequence confirmed and used to
express and purify the encoded fusion proteins (Fig. 1B). Longer
DNA fragments encoding PfEMP3's highly repetitive regions
(Fig. 1A) could also not be cloned in full length, therefore
representative fragments of these repeat regions were cloned and
used for protein expression. The resulting purified MBP-PfEMP3
fusion proteins used in the interaction assays are shown in
(Figs. 1C, 2B and 4B). Immunoblot detection using polyclonal
anti-MBP sera was performed on all purifiedMBP fusion proteins
to demonstrate presence of the MBP tag and confirm the identity
of each protein (data not shown).
3.2. Mapping the PfEMP3 RBC membrane skeleton binding
domain
IOVs prepared from normal human RBCs using the method-
ology described possess spectrin and actin in a properly linked
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brane skeleton proteins (for review, see Fairbanks et al. [35]). A
sample of prepared IOVs was resolved by SDS-PAGE and
stained with Coomassie Brilliant Blue to confirm the presence
of the major RBC membrane skeleton proteins, including spec-
trin and actin (data not shown).Fig. 4. Mapping the region of PfEMP3 that binds to spectrin. (A) Schematic representa
immunoblots. Spectrin (lanes 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27) and BSA
the 96-well plate prior to adding MBP-PfEMP3 fusion proteins or MBP control protein
(lanes 7 and 8), -FIV (lanes 9 and 10), -FV (lanes 11 and 12), -FIa (lanes 15 and 16), -FIb
and 26) and -Fla.4 (lanes 27 and 28). Fragment -FI and its successively smaller sub-fragm
BSA (lanes 4, 16 and 22, respectively). These data map the region of PfEMP3 that binAn initial series of IOV interaction assays were performed
using the MBP-PfEMP3 fusion proteins -FI (residues 38–587 of
full length PfEMP3), -FII (residues 588–901), -FIII (residues
1069–1320), -FIV (residues 1319–1428) and -FV (residues
2368–2441) to broadly map the region of PfEMP3 that binds to
the RBC skeleton. A representative immunoblot is shown intion of PfEMP3 and its sub-fragment proteins. (B, C and D) Spectrin binding assay
(lanes 2, 4, 6, 8, 10, 12, 14, 16,18, 20, 22, 24, 26 and 28) were coated on thewells of
: MBP (lanes 1, 2, 13, 14, 19 and 20), -FI (lanes 3 and 4), -FII (lanes 5 and 6), -FIII
(lanes 17 and 18), -FIa.1 (lanes 21 and 22), -FIa.2 (lanes 23 and 24), -Fla.3 (lanes 25
ents -FIa and -Fla.1 all bound to IOVs (lanes 3, 15 and 21, respectively) but not to
ds to spectrin to the same 60 residues that bind to IOVs.
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4), whereas the -FII, -FIII, -FIVand -FV fragments and MBP did
not bind to either IOVs or BSA (lanes 5 through 12, respectively).
These initial interaction assays indicated that residues 38–587 of
PfEMP3 contain the binding domain for RBCmembrane skeleton
protein(s). Subsequent division of -FI into -FIa (residues 38–271)
and -FIb (residues 269–587) protein sub-fragments further
refined the binding domain to a 234-residue region, as evidenced
by the binding of -FIa to IOVs (lane 15), but not to BSA (lane 16).
To further define the PfEMP3 skeleton-binding domain,
smaller protein fragments were generated. Representative im-
munoblots of binding assays using these proteins (Fig. 2C and D)
show that -FIa.1 (residues 38–97), a 60-residue fragmentFig. 5. Deletion mapping of PfEMP3 binding to spectrin. (A) Schematic represen
fragments and deletion fragments used to map the spectrin binding domain. (B) Addi
2 μg (total protein) of each purified protein was resolved by SDS-PAGE and stained w
(lane 2), −54–98 (lane 3) and −38–53 (lane 4). (C and D) Spectrin binding assay im
(lanes 2, 4, 6, 8, 10, 12, 14, 16,18, 20, 22 and 24) were coated on the wells of the 96-w
MBP (lanes 1, 2, 7, 8, 15 and 16), MBP-PfEMP3-FIa (lanes 3 and 4), -FIaΔFIa.1 (lan
13 and 14), -FIaΔ53 (lanes 17 and 18), −54–67 (lanes 19 and 20), −54–83 (lanes 2
mutant -FIaΔ53 (lane 9 and 17) and −54–67, −54–83 and −54–98 (lanes 19, 21 and
minimal binding region of PfEMP3 to spectrin to the 14-residue region represented(FTVVKNYNKIDNVYNIFEIRLKRSLAQVLGNTRLSSRG-
VRDPRTKEALKEKQFRDHKRKE) of -FI, binds to IOVs (Fig.
2C, lane 3), but not to BSA (lane 4). Other sub-regions (-FIa.2,
-FIa.3 and -FIa.4, corresponding to residues 98–156, 157–214
and 215–271, respectively) were also examined for binding
ability. None of these bound to IOVs or to BSA (lanes 5 through
10, respectively). Based on these data, several deletion mutant
PfEMP3 protein sub-fragments were generated. PfEMP3–
FIaΔFIa.1, in which residues 38–97 had been deleted did not
bind to IOVs or BSA (Fig. 2D, lanes 15 and 16, respectively).
The deletion mutant proteins -FIaΔ53 bound to IOVs but not to
BSA (lanes 19 and 20), whereas -FIaΔ67 and -FIaΔ83 did not
bind to either IOVs (lanes 21 and 23, respectively) or BSA (lanestation of PfEMP3-FI region (residues 38–592) and the smaller PfEMP3 sub-
tional MBP-PfEMP3 fusion proteins that were used in these analyses are shown.
ith Coomassie Brilliant Blue. The protein samples are: −54–67 (lane 1), −54–83
munoblots. Spectrin (lanes 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23) and BSA
ell plate prior to adding MBP-PfEMP3 fusion proteins or MBP control protein:
es 5 and 6), -FIaΔ53 (lanes 9 and 10), -FIaΔ67 (lanes 11 and 12), -FIaΔ83 (lanes
1 and 22) and −54–98 (lanes 23 and 24). PfEMP3-FIa (lane 3) and its deletion
23, respectively) each bound to spectrin only. Taken together, these data map the
on the protein fragment −54–67.
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PfEMP3 that binds to the RBC membrane skeleton to residues
54–67 (14 residues in total; IFEIRLKRSLAQVL).
Confirmatory evidence for the association of PfEMP3
with the membrane skeleton was obtained from TX100
extraction of lysed and resealed RBCs that had been incubated
in the presence of 5 μM MBP-PfEMP3-FI or -FV fusion
proteins. MBP-PfEMP3-FI was detected in both the TX100
soluble and insoluble fractions (Fig. 3, lanes 1 and 2, res-
pectively), whereas -FV was detected only in the TX100
soluble fraction (lane 3). Similarly extracted lysed RBC
controls are also shown (lanes 5 and 6). Collectively, these
data demonstrate the classical detergent solubility profiles
characteristic of skeleton-associated proteins and define this
membrane skeleton binding region of PfEMP3 to the 14-
residue region IFEIRLKRSLAQVL.
3.3. PfEMP3 binds to spectrin
To determine if PfEMP3 and spectrin are binding partners,
we performed binding assays between fragments of PfEMP3
and purified spectrin (Figs. 4 and 5). Similar to the above IOV
binding assays, PfEMP3-FI and its sub-fragments -FIa and
-FIa.1 bound to spectrin (Fig. 4B, C and D, lanes 3, 15 and 21,
respectively), but not to BSA (Fig. 4B, C and D, lanes 4, 16
and 22, respectively). These assays defined the region of
PfEMP3 that binds to spectrin to the same 60-residue region
that bound IOVs in earlier experiments. Further assays used
the smaller PfEMP3 deletion and sub-fragment proteins (Fig.
5A). The -FIa fragment bound to spectrin (Fig. 5C, lane 3) but
its deletion mutant -FIaΔFIa.1, which lacks residues 38–97,
failed to bind to spectrin (lane 5). The deletion mutant
-FlaΔ53 bound to spectrin (lanes 9 and 17), whereas -FlaΔ67
and -FlaΔ83 failed to bind (lanes 11 and 13, respectively).
Use of smaller fragments spanning the 60-residue region
showed that −54–67 bound to spectrin at low levels (lane 19),
with increasing binding levels observed for −54–83 (lane 21)
and −54–98 (lane 23). Taken together, these data define the
minimal binding region of PfEMP3 for spectrin to the sameTable 2
Quantitation of the interaction between PfEMP3 and Spectrin
PfEMP3 fragments ka (M
−1 s−1) kd (s
−
FI 3.0±0.1×104 2.110.
FII, FIII, FIV, FV No binding No bin
FIa 8.4± 0.1×104 6.3±0
FIb No binding No bin
FIa.1 7.9±0.2×104 6.7±0
FIa.2, FIa.3, FIa.4 No binding No bin
FIaΔFIa.1 No binding No bin
FIaΔ53 2.4±0.2×103 6.6±0
FIaΔ67 No binding No bin
38–53 No binding No bin
54–67 15±0.2×103 5.7±0
MBP No binding No bin
Purified MBP-PfEMP3 fusion proteins and purified RBC spectrin were used in int
Cambridge, UK). The binding assays were performed as previously described [17] in
the resonant mirror detection method, ka, kd, KD(kin) and KD(Scat) were determined u14-residue region (IFEIRLKRSLAQVL) that binds IOVs.
These data also indicate the presence of sequences down-
stream of the 14-residue region that act to increase the
intensity of binding to spectrin conferred by the 14-residue
region.
3.4. Kinetic analysis of PfEMP3–spectrin interactions
An IAsys™ system was used to determine the kinetics of the
observed interactions. Biophysical data were obtained using
aminosaline cuvettes coated with spectrin or BSA and PfEMP3
proteins were applied in aqueous solution. The data obtained
(ka, kd and subsequent KD(kin) and KD(Scat) ) are shown in Table 2.
These data are in accordance with the microtitre plate inter-
action data and show strong, saturable interactions between
spectrin and PfEMP3 fragments -FI (KD(kin)=7.0×10
−8 M), -FIa
(KD(kin)=7.5×10
−8 M) and -FIa.1 (KD(kin)=8.5×10
−8 M) and no
interaction with any of the other fragments. No interaction was
observed between -FIaΔFIa.1 and spectrin, again confirming
the binding region as the 60 residues encoded by -FIa.1. KD(kin)
data were also obtained using the PfEMP3 deletion mutants pro-
teins. PfEMP3–FIaΔ53 bound strongly to spectrin coated cuvettes
(KD(kin)=2.75×10
−7 M), but -FIaΔ67 did not. Kinetic analyses
using protein −38–53 showed no binding, but strong binding of
protein −54–67 to spectrin (KD(kin)=3.80×10−7 M), respectively.
These data further confirm the region of PfEMP3 that binds to
spectrin is encoded in the14-residue sequence (IFEIRLKRSLAQVL)
contained within PfEMP3 sub-fragment −54–67.
3.5. PfEMP3 binds to F-actin
To detect interactions between polymerised F-actin and
regions of PfEMP3, co-sedimentation assays were used. Under
the sedimentation conditions used, F-actin was found predomi-
nantly in the pellet, whereas monomeric G-actin was found
mostly in the supernatant fraction (Fig. 6A). Subsequently, equi-
molar concentrations of F-actin and recombinant MBP-PfEMP3
fusion proteins were interacted and co-sedimented. Resultant
supernatant and pellet fractions were analysed by immunoblot1) KD(kin) (μM) KD(Scat) (μM)
1×10−3 0.07 0.059
ding No binding No binding
.2×10−3 0.075 0.067
ding No binding No binding
.1×10−3 0.085 0.080
ding No binding No binding
ding No binding No binding
.2×10−4 0.275 0.236
ding No binding No binding
ding No binding No binding
.2×10−4 0.380 0.300
ding No binding No binding
eraction assays using an IAsys™ resonant mirror biosensor (Affinity Sensors,
PBS containing 0.05% (v/v) Tween 20. From the binding curves obtained using
sing the software package FASTFIT™.
Fig. 6. The Region of PfEMP3 that Binds to Actin. (A) Preliminary co-
sedimentation assays were performed using polymerised F-actin and monomeric
G-actin. Samples of F-actin and G-actin were then centrifuged at 25 °C for
10 min at 85,000 rpm (313,000×g). Pellet and supernatant samples from each
reaction were then resolved by SDS-PAGE in 10% (w/v) polyacrylamide gels
and stained with Coomassie Brilliant Blue. Nearly all the polymerised F-actin
was found in the pellet fraction (P), whereas most of the monomeric G-actin was
found in the supernatant fraction (S). Only residual levels of actin were observed
in the other fractions. (B) Eqi-molar solutions (5 μM) of F-actin and
recombinant MBP-PfEMP3 fusion proteins were interacted and co-sedimented.
Immunoblot analysis of resultant supernatant and pellet fractions was
performed. Representative immunoblots show MBP alone is unable to bind F-
actin, whereas the MBP-PfEMP3-F1a.1 fusion protein co-sedimented in the
presence of F-actin, (although a proportion of the recombinant protein also
remained in solution). (C) Eqi-molar solutions (5 μM) of F-actin and purified
MBP-PfEMP3 fusion proteins were interacted and then co-sedimented. The
pellet and supernatant fractions were resolved by SDS-PAGE and the
immunoblot data analysed by densitometry. The graphed data show pelleting
of F-actin with -FI, and its successively smaller sub-fragments, -FIa, -FIa.1.
Deletion mutagenesis further defined the binding region to 14 residues (residues
54–67 of PfEMP3), as evidenced by -FIaΔ53 pelleting with F-actin, whereas
-FIaΔ67 did not. The presence of only these 14 residues in the −54–67 fragment
also resulted in pelleting with F-actin. (D) Binding of F-actin to -FIa was
demonstrated to be specific and saturable. Constant 5 μM actin was incubated
with titrated serial dilutions of -FIa and centrifuged. Pellet and supernatant
fractions were analysed by immunoblot, using anti-MBP and anti-actin
antibodies and subsequent densitometry. (E) Saturation of binding curve
constructed from densitometric analyses of titrated -FIa co-sedimented with
constant 5 μM actin (Fig. 5D). The graphed data are from a representative assay
(mean±standard deviation).
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F-actin, whereas the MBP-PfEMP3-FIa.1 fusion protein co-
sedimented with F-actin, (although a proportion of the recom-
binant protein also remained in solution). In further immunoblots,
densitometry was used to determine the percentage of recom-
binant protein in the pellet, corrected by subtraction of the % of
recombinant protein that pelleted in the absence of F-actin, and
the resultant data graphed (Fig. 6C). Interestingly the MBP-
PfEMP3 fusion proteins that were found to pellet, and therefore to
bind F-actin, were consistent with those that were also shown to
bind spectrin. Fragments -FI, -FIa and -FIa.1 bind to F-actin,
whereas the other fragments show no binding (Fig. 6C). Deletion
analysis confirmed the same 60-residue region as the binding
domain, as evidenced by the inability of -FIaΔFIa.1 to bind F-
actin. Further deletion analysis showed that residues 38–53 were
not essential for binding, however deletion of further residues
within this larger region resulted in only a partial loss of binding.
This was evidenced by binding of -FIaΔ53, but only partial
binding of -FIaΔ67 and -FIaΔ83. These data again show that
residues 54–67 are sufficient to confer almost all binding
observed by the 60-residue region encoded by -FIa.1, however
the presence of other residues downstream of the 14-residue
region appear to increase the intensity of interaction, almost to the
level detected for -FIa.1 (Fig. 6C).
Further, co-sedimentation assays demonstrated that the
interaction between F-actin and PfEMP3-FIa.1 is specific and
saturable (Fig. 6D). Constant 5 μM F-actin was interacted with
titrated serial dilutions of PfEMP3-FIa (from 5 μM to 0.0 μM)
and the negative control protein PfEMP3-FV (1.25 μM and
2.5 μM). Immunoblots of a representative experiment are shown
(Fig. 6D), and the corresponding densitometric data corrected by
subtraction of the relative percentage amount of PfEMP3-FV
pelleted in the absence of F-actin. Graphical representation of this
saturation of binding curve is shown in Fig. 6E.
4. Discussion
Here, we have characterised the interactions that bind
PfEMP3 to the membrane skeleton of IRBCs. We have used a
recombinant protein approach and two independent in vitro
assays to identify spectrin as a binding partner for PfEMP3 and
to map the minimal binding domain a 14-residue sequence,
IFEIRLKRSLAQVL, corresponding to residues 54–67 of
PfEMP3. Additionally, biosensor assays determined moderately
high affinity interactions between various fragments of PfEMP3
and spectrin (Table 2; -FIa (KD(kin)=7.0×10
−8 M) and its 60-
residue sub-fragment -FIa.1 (KD(kin)=8.5×10
−8 M)). Deletion
of these 60 residues (38–97) in -FIaΔFIa.1 abolished binding,
whereas deletion of residues 38–53 of this region in -FIaΔ53
retained binding ability (KD(kin)=2.75×10
−7 M), but deletion
of residues 38–67 in -FIaΔ67 abolished binding (Table 2).
Positive confirmation of these 14 residues conferring the bind-
ing domain of PfEMP3 to spectrin was obtained using the
protein −54–67 (KD(kin)=3.8×10−7 M). A low level of −54–67
binding to spectrin was also detected (Fig. 5), with binding
levels showing modest increases when residues down stream of
the 54–67 residue region were included in the proteins −54–83
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in the actin co-sedimentation assays (Fig. 6C), where residues
downstream of the 14-residue region appeared to increase the
intensity of the interaction. Such enhancement of interactions by
adjacent residues has previously been reported in the binding of
the parasite protein MESA to its binding partner protein 4.1R
[36]. The observation that the PfEMP3–membrane skeleton
interaction occurs in vitro to IOVs, where the supramolecular
structure of the spectrin-actin network and the conformation of
the individual proteins is conserved, as well as in vivo provides
confidence that this is a physiologically relevant interaction.
In a previous study using various truncated constructs of
PfEMP3 fused to green fluorescent protein, Knuepfer and
colleagues demonstrated peripheral localisation of a transgene
product containing the first 500 residues of PfEMP3, but not of
products composed of only the first 66 or 88 PfEMP3 residues
when those constructs were transfected into P. falciparum
parasites. Products of 120 residues fused to GFP showed some
weak peripheral association [23]. The authors concluded that a
region between residues 120 and 500 is responsible for both the
tight association they described with Maurer's clefts and the
membrane skeleton. These results are in apparent contradiction
to those reported here, where we define the membrane skeleton-
binding domain to sequences in the first 97 residues of PfEMP3.
These results may be reconciled if we propose that only proteins
that are trafficked via the Maurer's clefts are in the correct
conformation and localisation to bind to spectrin and actin at the
membrane skeleton. The shorter constructs would fail to bind,
either because of steric hindrance due to the presence of GFP as
has previously been reported [37] or because of failure to
properly expose binding domains on either the host or parasite
proteins. This proposition could be tested by tracking of a
chimeric PfEMP3 construct lacking the first 67 residues of
PfEMP3. At any rate, using the techniques described in this
paper, we were unable to detect any other membrane skeleton
binding domains within residues 120–500 of PfEMP3 and
conclude that efficient association of this protein with the
membrane skeleton requires trafficking in the protein aggre-
gates associated with Maurer's clefts [23]. Interestingly, the 14-
residue region identified here as the spectrin and actin binding
domain of PfEMP3 (IFEIRLKRSLAQVL) also contains the
putative VTS/PEXEL motif RSLAQ. This motif has recently
been described as a common sequence that results in the traf-
ficking of parasite proteins across the parasitophorous vacuole
and into the red cell cytosol [27,28]. Many of the 300–400
proteins that have this sequence do not interact with the red cell
membrane skeleton. In the case of PfEMP3, the region of
sequence common to recombinant proteins that bind to spectrin
is a 14-residue sequence that includes the VTS/PEXEL.
Whether any residues that contribute to membrane skeleton
binding are part of the VTS/PEXEL is not known, however, the
lack of membrane skeleton association of many VTS/PEXEL
proteins leads us to conclude that it is the flanking residues in
this 14-residue region that are most likely to be responsible for
the association with spectrin.
The affinity of the interaction between the 14-residue PfEMP3
region encoded by recombinant PfEMP3 protein -FIa.1 (residues38–98) and spectrin (KD(kin)=8.5×10
−8 M) is of similar
magnitude to the affinity of other protein–protein interactions
occurring at the RBC membrane skeleton. Thus, in uninfected
RBCs, protein 4.1 binds to p55 with moderate affinity (Kd=
2.5×10−9 M; [38]), protein 4.2 binds to band 3 with a Kd=2–
8×10−7 M; [39], and protein 4.2 binds to ankyrin with Kd=1–
3.5×10−7 M [39]. This level of binding is also typical of that
seen for malaria proteins binding at the membrane skeleton to
host or malaria proteins. These include protein 4.1 and MESA
(KD(kin)=1.3×10
−7 M; [11]) and between KAHRP and PfEMP1
(KD(kin)=1×10
−7 M; [17]).
We have identified the same 14-residue region of PfEMP3
(IFEIRLKRSLAQVL) as the binding region for both spectrin
and actin. The capacity of a single domain to interact with two
distinct host proteins has not previously been reported for other
well-characterised malaria protein interactions at the RBC
membrane. Although KAHRP has been shown to be capable of
binding to PfEMP1, spectrin, ankyrin and actin, different
regions of KAHRP were responsible for binding to each
protein [15–18]. Since it is not known precisely which domain
on spectrin is bound by PfEMP3, it is unclear whether a single
molecule of PfEMP3 could simultaneously bind molecules of
both spectrin and actin. Binding may be a stochastic process
with PfEMP3 molecules binding one or other potential binding
partner at random. This would lead to a somewhat random
localisation with respect to knobs, which is indeed what has
been observed [21]. Perhaps also, this dual binding capability
has evolved to provide a large number of potential binding
sites to anchor this protein. As KAHRP is also capable of
binding actin, these two malaria proteins may be expected to
compete for actin binding sites at the membrane skeleton.
Previous rheological studies have already shown increased
rigidification of the RBC membrane in parasites that express
and localise PfEMP3 at the RBC skeleton [40] and this
probably requires a sufficient number of the highly charged
PfEMP3 molecules to be bound at the membrane, which the
availability of additional binding sites would help ensure.
Alternatively, it may be that PfEMP3 binding distorts the
membrane skeleton in a way that brings together the binding
domains on spectrin and actin and leads to membrane
rigidification. This might also be responsible for the distorted
appearance of the RBC that is almost always seen in scanning
electron micrographs of IRBCs.
Previous rheological studies have also demonstrated a lower
extent of rigidification of the RBC membrane skeleton in RBCs
infected with a specific pfemp3 gene knockout parasite [40].
This observation, in conjunction with the data presented in this
study, supports our working hypothesis that PfEMP3 may
rigidify the RBC membrane skeleton by initiating novel protein
interactions (PfEMP3–spectrin and PfEMP3–actin interac-
tions) or by altering the affinity of other protein interactions at
the IRBC skeleton. As such, PfEMP3 may act in an analogous
fashion to protein 4.1, which strengthens the low affinity
(Ka=5×10
−3 M−1) spectrin–actin interaction by several orders
of magnitude (spectrin–actin–protein 4.1; Ka=1×10
−12 M−2)
[41]. Alternatively, the presence of PfEMP3 at the RBC ske-
leton may have a competitive effect on other established
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actin–protein 4.1 [41], spectrin–ankyrin [42], spectrin–actin–
adducin [43], actin–dematin [44], actin–tropomyosin [44] and
actin–tropomodulin [45]. In order to clarify the likely effect
PfEMP3 has on other protein interactions in the RBCmembrane
skeleton, further mapping studies would be required to define
the domain in spectrin and actin that binds PfEMP3, and to
determine if these domain(s) overlap with previously described
binding domains in spectrin. The N-terminal region of β-
spectrin contains the binding domain for actin and protein 4.1,
whereas the ankyrin binding site has been mapped to a region
near the C-terminal region of β-spectrin [46–48]. It is also
possible that PfEMP3 may act in collaboration with other
parasite-encoded proteins, such as PfEMP1 and KAHRP, both
of which have been shown to interact with spectrin and actin
[14,18]. Further mapping of the protein interacting domains of
PfEMP3 and other parasites proteins with the RBC membrane
skeleton will help to elucidate this complicated set of inter-
actions and facilitate our understanding of the changes induced
in the architecture of the membrane skeleton of P. falciparum-
IRBCs and their subsequent impact on the pathophysiology of
malaria.
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